Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

France Carrier

France Carrier

University Of Maryland, USA

Title: Chemopotenetiation By Low-Dose-Fractionated Radiation Therapy

Biography

Biography: France Carrier

Abstract

The emerging concept of chemopotentiation by Low Dose Fractionated Radiation Therapy (LDFRT) is not fully understood but builds on the phenomenon of low-dose hyper-radiosensitivity (HRS). This new paradigm allows the use of full dose systemic chemotherapy safely in combination with LDFRT, where the low-dose radiation sensitizes the tumor to subsequent chemotherapy. Using a RT2 PCR Profiler Array we identified Dual Oxidase 2 (DUOX2), an enzyme functioning in the production of hydrogen peroxide, as a major mediator of chemopotentiation by LDFRT. Down regulation of DUOX2 increased radioresistance at every radiation doses tested. In addition, our data indicate that Reactive Oxygen Species increase up to 3.5 fold in cells exposed to LDFRT and a modified regimen of Docetaxel, Cisplatin, and 5’-fluorouracil (mDCF). Furthermore, inhibition of NADPH oxidase abrogated the killing efficiency of this combined regimen in human gastric cancer cells. Taken together these data suggest that chemopotentiation by LDFRT may be due, at least in part, to increased ROS production (DUOX2) without upregulation of the DNA repair machinery. These data thus provide a rationale for further explorations of potential clinical applications of LDFRT, such as in Whole abdominal radiotherapy, as a chemopotentiator for advanced and metastatic gastric cancers.